Bavarian Nordic (BAVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bavarian Nordic (BAVA) has a cash flow conversion efficiency ratio of 0.042x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr545.05 Million ≈ $85.28 Million USD) by net assets (Dkr12.87 Billion ≈ $2.01 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bavarian Nordic (BAVA) net asset quality to measure how much of total assets are equity-financed.
Bavarian Nordic - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Bavarian Nordic's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BAVA cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Bavarian Nordic Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bavarian Nordic ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Transportadora de Gas del Sur SA ADR
NYSE:TGS
|
0.045x |
|
Afi Properties Ltd
TA:AFPR
|
0.014x |
|
Construcciones y Auxiliar de Ferrocarriles S.A.
MC:CAF
|
0.141x |
|
Computer Age Management Services Limited
NSE:CAMS
|
0.028x |
|
La Comer S.A.B. de C.V
MX:LACOMERUBC
|
0.033x |
|
Lotus Health Group Co
SHG:600186
|
0.052x |
|
REMEGEN CO. LTD YC 1
F:REG
|
N/A |
|
Southchip Semiconductor Technology (Shanghai) Co. Ltd. A
SHG:688484
|
-0.024x |
Annual Cash Flow Conversion Efficiency for Bavarian Nordic (2001–2025)
The table below shows the annual cash flow conversion efficiency of Bavarian Nordic from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Bavarian Nordic.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Dkr12.87 Billion ≈ $2.01 Billion |
Dkr2.72 Billion ≈ $425.86 Million |
0.211x | +23.74% |
| 2024-12-31 | Dkr11.41 Billion ≈ $1.78 Billion |
Dkr1.95 Billion ≈ $305.07 Million |
0.171x | +57.90% |
| 2023-12-31 | Dkr10.34 Billion ≈ $1.62 Billion |
Dkr1.12 Billion ≈ $175.11 Million |
0.108x | +251.70% |
| 2022-12-31 | Dkr7.15 Billion ≈ $1.12 Billion |
Dkr220.05 Million ≈ $34.43 Million |
0.031x | +163.31% |
| 2021-12-31 | Dkr7.37 Billion ≈ $1.15 Billion |
Dkr-358.50 Million ≈ $-56.09 Million |
-0.049x | -141.60% |
| 2020-12-31 | Dkr4.89 Billion ≈ $765.76 Million |
Dkr571.91 Million ≈ $89.48 Million |
0.117x | +179.00% |
| 2019-12-31 | Dkr1.87 Billion ≈ $291.86 Million |
Dkr-275.91 Million ≈ $-43.17 Million |
-0.148x | -11.78% |
| 2018-12-31 | Dkr2.18 Billion ≈ $341.18 Million |
Dkr-288.53 Million ≈ $-45.14 Million |
-0.132x | -253.48% |
| 2017-12-31 | Dkr2.51 Billion ≈ $392.13 Million |
Dkr216.06 Million ≈ $33.80 Million |
0.086x | -35.01% |
| 2016-12-31 | Dkr2.02 Billion ≈ $315.61 Million |
Dkr267.60 Million ≈ $41.87 Million |
0.133x | +69.09% |
| 2015-12-31 | Dkr1.34 Billion ≈ $210.04 Million |
Dkr105.32 Million ≈ $16.48 Million |
0.078x | -71.00% |
| 2014-12-31 | Dkr1.25 Billion ≈ $195.90 Million |
Dkr338.75 Million ≈ $53.00 Million |
0.271x | +79.58% |
| 2013-12-31 | Dkr976.29 Million ≈ $152.75 Million |
Dkr147.08 Million ≈ $23.01 Million |
0.151x | +649.29% |
| 2012-12-31 | Dkr999.68 Million ≈ $156.41 Million |
Dkr20.10 Million ≈ $3.14 Million |
0.020x | +106.47% |
| 2011-12-31 | Dkr1.21 Billion ≈ $188.94 Million |
Dkr-375.24 Million ≈ $-58.71 Million |
-0.311x | -4.99% |
| 2010-12-31 | Dkr810.43 Million ≈ $126.80 Million |
Dkr-239.86 Million ≈ $-37.53 Million |
-0.296x | +56.95% |
| 2009-12-31 | Dkr704.21 Million ≈ $110.18 Million |
Dkr-484.14 Million ≈ $-75.75 Million |
-0.687x | -3214.05% |
| 2008-12-31 | Dkr1.02 Billion ≈ $158.82 Million |
Dkr22.41 Million ≈ $3.51 Million |
0.022x | -83.52% |
| 2007-12-31 | Dkr1.22 Billion ≈ $190.51 Million |
Dkr163.16 Million ≈ $25.53 Million |
0.134x | +147.63% |
| 2006-12-31 | Dkr691.40 Million ≈ $108.17 Million |
Dkr-194.49 Million ≈ $-30.43 Million |
-0.281x | -204.50% |
| 2005-12-31 | Dkr630.10 Million ≈ $98.58 Million |
Dkr-58.21 Million ≈ $-9.11 Million |
-0.092x | +61.98% |
| 2004-12-31 | Dkr315.39 Million ≈ $49.35 Million |
Dkr-76.63 Million ≈ $-11.99 Million |
-0.243x | -40386.52% |
| 2003-12-31 | Dkr347.00 Million ≈ $54.29 Million |
Dkr209.27K ≈ $32.74K |
0.001x | +100.86% |
| 2002-12-31 | Dkr196.44 Million ≈ $30.73 Million |
Dkr-13.71 Million ≈ $-2.15 Million |
-0.070x | +96.69% |
| 2001-12-31 | Dkr44.14 Million ≈ $6.91 Million |
Dkr-93.12 Million ≈ $-14.57 Million |
-2.109x | -- |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more